Publications by authors named "Noam Ponde"

Claim this Profile
A
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.
Christian Maurer, Elisa Agostinetto, Lieveke Ameye, Matteo Lambertini, Samuel Martel, Noam Ponde

Breast Cancer Res Treat· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
Bianca Lara Venâncio de Godoy, Marina Gobbe Moschetta-Pinheiro, Luiz Gustavo de Almeida Chuffa, Noam Falbel Pondé, Russel J Reiter

Life Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.
Matteo Lambertini, Shona Fielding, Sibylle Loibl, Wolfgang Janni, Emma Clark, Noam F Ponde

J Natl Cancer Inst· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé

NPJ Breast Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.
Maria Alice Franzoi, Marion Procter, Chris Twelves, Noam Ponde, Daniel Eiger

Ecancermedicalscience· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A Korde, Florentine Hilbers

Breast Cancer Res Treat· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.
Shah Zeb Khan, Luca Arecco, Cynthia Villarreal-Garza, Bhawna Sirohi, Noam F Ponde

JCO Glob Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined endocrine and targeted therapy in luminal breast cancer.
Marcelle Goldner, Natasha Pandolfi, Debora Maciel, Julianne Lima, Solange Sanches

Expert Rev Anticancer Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
Luciana de Moura Leite, Marcelle Goldner Cesca, Monique Celeste Tavares, Debora Maciel Santana, Erick Figueiredo Saldanha

Breast Cancer Res Treat· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Elisa Agostinetto, Daniel Eiger, Matteo Lambertini, Marcello Ceppi, Marco Bruzzone

Eur J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Maria Alice Franzoi, Daniel Eiger, Lieveke Ameye, Noam Ponde, Rafael Caparica

J Natl Cancer Inst· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
Arlindo R Ferreira, Sofia Ferreira, Matteo Lambertini, Christian Maurer, Samuel Martel, Noam Ponde

Eur J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A Korde, Florentine Hilbers

Breast Cancer Res Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, Noam F Ponde, Andrea Gombos

J Natl Compr Canc Netw· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are We RESPECTing Older Patients With Breast Cancer?
Evandro de Azambuja, Noam Pondé, Richard D Gelber

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, Noam F Ponde, Francesca Poggio

ESMO Open· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of early breast cancer in patients bearing germline BRCA mutations.
Marie-Daphné t'Kint de Roodenbeke, Noam Pondé, Laurence Buisseret, Martine Piccart

Semin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-positive advanced breast cancer treatment in 2020.
Marcelle G Cesca, Lucas Vian, Sofia Cristóvão-Ferreira, Noam Pondé, Evandro de Azambuja

Cancer Treat Rev· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
Mariana Brandão, Christian Maurer, Patricia Klarmann Ziegelmann, Noam F Pondé, Arlindo Ferreira

ESMO Open· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.
Amir Sonnenblick, Mali Salmon-Divon, Roberto Salgado, Efrat Dvash, Noam Pondé

Int J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-HER2 therapy for breast cancer in older patients.
Marcelle Goldner, Maria A Franzoi, Lissandra D Lago, Noam Pondé

Future Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Daniel Eiger, Marcio Wagner, Noam F Pondé, Melanie S Nogueira, Laurence Buisseret

Acta Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, Alvaro Moreno-Aspitia, Martine Piccart

Br J Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
Noam Pondé, Lieveke Ameye, Matteo Lambertini, Marianne Paesmans, Martine Piccart

Eur J Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.
Daniel Eiger, Maria Alice Franzoi, Noam Pondé, Mariana Brandão, Claudia de Angelis

ESMO Open· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis